Immunization

A majority of long-term care patients who received a fourth vaccination against COVID-19 were found to have increased protection against the omicron variant.

People who are afraid of shots or feel lightheaded and dizzy while near vaccine injection sites are less likely to get vaccinated against COVID-19.

Individuals vaccinated simultaneously with COVID-19 booster and influenza vaccines may be more likely to experience systemic reactions and adverse health impacts.

There are many changes that need to be made on multiple levels of healthcare to combat health disparities and equity.

Pharmacists are in an excellent position to educate and counsel patients on current recommendations.

Persistence by pharmacists and showing patients respect can help overcome misinformation.

The investigational PCV is designed to target serotypes responsible for 85% of all invasive cases of the disease in individuals aged 65 and older in the United States.

A pharmacist’s role in the ambulatory care setting has traditionally included a review of medications for potential drug-drug interactions and adverse events, medication reconciliation, and the provision of counseling services.

There is new guidance needed for pediatric immunizations, and pharmacists should be prepared for what's to come.

The FDA approved a licensure request for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, and Fluzone Quadrivalent for use in the upcoming 2022-2023 flu season, providing influenza vaccination for adults 65 years of age and older.

Rates of influenza and associated hospitalizations demand late-season vigilance.

Companies, FDA caught unaware by surge in virus cases, leading to shortage of critical items.

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

The FDA approved the first vaccine for dengue disease in May 2019.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

Pharmacy and public health have a long history of collaboration during an emergency.

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

The survey results come as the ACIP evaluates data to provide guidance for flu vaccines in older adults.

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.

Vaccinations are a critical preventive vaccinations are a critical preventive health measure and are routinely recommended from an early age. Indeed, the first hepatitis B vaccine in the series can be administered within 12 to 24 hours of birth.

Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.